 The purpose of this study is to examine the safety, local tolerability and pharmacokinetics how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time of a single intramuscular injection injected directly in the muscle of 300 mg Panel 1 or 600 mg Panel 2 of a new long acting form of TMC278. In Panel 3, the safety, local tolerability and pharmacokinetics are being studied after three successive intramuscular injections single injection on Day1, single injection on Day15 and single injection on Day43 of a selected dose of the same TMC278 LA formulation. The dose of Panel 3 will be determined based on the safety, local tolerability and the pharmacokinetic results obtained in Panel 1 and 2. 